Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,988 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer Disease
Interventions
MK-2214, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
12
States / cities
Glendale, California • Los Alamitos, California • Orange, California + 9 more
Conditions
Alzheimer's Disease
Interventions
LY451395
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
9
States / cities
Beverly Hills, California • Fresno, California • Boca Raton, Florida + 6 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Healthy Patterns Sleep Study

NCT03682185
Conditions
Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder, Insomnia, Hypersomnia, Cognitive Impairment, Cognitive Decline, Mild Cognitive Impairment, Frontotemporal Dementia, Neurocognitive Disorders, Vascular Dementia, Sleep Disorder, Memory Impairment
Interventions
Attention-Control Condition, Timed Activity Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
421 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
high CBD/low THC sublingual solution
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

R21 Roche: 3-Way Tau Tracers in AD

NCT05464368
Conditions
Alzheimer Disease
Interventions
[18F]RO-948, 18F-MK6240, 18F-GTP1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Alzheimer's Disease
Interventions
Home based occupational therapy, Best practices primary care
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
45 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Alzheimer's Disease
Interventions
MK-1708, Itraconazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
South Miami, Florida
Conditions
Alzheimer Disease, Dementia, Primary Progressive Aphasia, Aphasia, Progressive Aphasia, Progressive Aphasia in Alzheimer's Disease
Interventions
Psychosocial educational, support group and implementation of strategies
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Austin, Texas
Conditions
Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegeneration, Inflammation, Brain
Interventions
Lenalidomide 10 mg, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Las Vegas, Nevada
Conditions
Alzheimer's Disease
Interventions
VHB937, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
22
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Tau in Alzheimer's Disease and Normal Aging

NCT03373604
Conditions
Alzheimer Disease
Interventions
18F-MK-6240, Lumbar Puncture (optional)
Drug · Procedure
Lead sponsor
Patrick Lao
Other
Eligibility
50 Years to 100 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer's Disease
Interventions
TRx0237 200 mg/day, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 89 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
58
States / cities
Phoenix, Arizona • Bellflower, California • Costa Mesa, California + 53 more
Conditions
Alzheimer's Disease
Interventions
Crenezumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 42 more
Conditions
Alzheimer's Disease
Interventions
Neramexane
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
34
States / cities
Peoria, Arizona • Phoenix, Arizona • Fresno, California + 30 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

An Objective Assessment Tool for Evaluating Functioning in Older Adults

NCT06489847
Conditions
Alzheimer Disease
Interventions
SPPB++ Application
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Alzheimers Disease
Interventions
[123-I] AV-83 Injection and Imaging Procedures
Radiation
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Completed No phase listed Observational Accepts healthy volunteers

Neurotrack Test Validation Protocol

NCT02608021
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer's Disease
Interventions
Semorinemab, Placebo, [18F]GTP1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
31
States / cities
Garden Grove, California • Los Alamitos, California • Palo Alto, California + 28 more
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Conditions
Alzheimer's Disease
Interventions
Bryostatin for Injection, Placebo
Drug
Lead sponsor
Blanchette Rockefeller Neurosciences Insitute
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more
Conditions
Cognitive Impairment, Alzheimer Blood Biomarkers, Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Interventions
Multimodal Lifestyle Intervention
Behavioral
Lead sponsor
HudsonAlpha Institute for Biotechnology
Other
Eligibility
65 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Huntsville, Alabama
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Conditions
Alzheimer's Disease
Interventions
aerobic exercise-training, stretch exercise
Behavioral
Lead sponsor
Howard University
Other
Eligibility
60 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania